Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy

The 2019 coronavirus disease (COVID-19) is the disease caused by SARS-CoV-2 infection. Although this infection has been shown to affect the respiratory system, a high incidence of thrombotic events has been observed in severe cases of COVID-19 and in a significant portion of COVID-19 nonsurvivors. A...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology. Heart and circulatory physiology Vol. 322; no. 1; pp. H87 - H93
Main Authors Seth, Ryan, McKinnon, Thomas A J, Zhang, X Frank
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.01.2022
SeriesVascular Biology and Microcirculation
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The 2019 coronavirus disease (COVID-19) is the disease caused by SARS-CoV-2 infection. Although this infection has been shown to affect the respiratory system, a high incidence of thrombotic events has been observed in severe cases of COVID-19 and in a significant portion of COVID-19 nonsurvivors. Although prior literature has reported on both the coagulopathy and hypercoagulability of COVID-19, the specifics of coagulation have not been fully investigated. Observations of microthrombosis in patients with COVID-19 have brought attention to potential inflammatory endothelial injury. Von Willebrand factor (VWF) and its protease, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13), play an important homeostatic role in responding to endothelial injury. This report provides an overview of the literature investigating the role the VWF/ADAMTS13 axis may have in COVID-19 thrombotic events and suggests potential therapeutic strategies to prevent the progression of coagulopathy in patients with COVID-19.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0363-6135
1522-1539
DOI:10.1152/AJPHEART.00204.2021